Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth ...
These Irish pubs have kept their doors open for centuries and proudly wear their age on their walls, all while serving up delicious pints of Guinness.
Opinion
4dOpinion
Surge to Save Newborns Coalition Launches with New Study Showing Cost to End State-by-State Newborn Screening Variability
The new study estimated it would cost $173 million to implement all RUSP-approved conditions across all 50 states, including those added in late 2025 and two anticipated future conditions.
The theme of this year’s conference is “Supporting you every step of the way: from diagnosis to transplant.” Kidney Action Week is a highlight of Kidney Month, with four days of educational sessions ...
10d
Your Kidneys Count: American Kidney Fund Urges Americans to Protect Their Health this Kidney Month
On March 1, the American Kidney Fund (AKF) will kick off Kidney Month by highlighting why Kidneys Count and how people can protect their kidney health. Kidney Month is observed every March and ...
Mirum Pharmaceuticals MIRM reported a loss of 11 cents per share in fourth-quarter 2025, against the Zacks Consensus Estimate ...
Travere Therapeutics Inc. (NASDAQ: TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, ...
The National Organization for Rare Disorders (NORD®) is calling attention to rare diseases as a significant and growing public health challenge affecting more than 30 million Americans. Fewer than 5 ...
Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late ...
Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results